Abstract 3360
Background
As slow disease progression is observed in a subset of mccRCC patients, watchful waiting can be considered, thereby postponing toxicity of systemic treatment. To identify those patients, the IMPACT trial evaluated the role of anti-Carbonic Anhydrase IX antibody 89Zr-girentuximab and 18F-fluorodeoxyglucose (FDG) PET/CT (PET). Here, we report preliminary analyses of a secondary endpoint: comparison of baseline contrast-enhanced(ce)CT, 89Zr-girentuximab and FDG PET to detect metastases.
Methods
mccRCC pts with good or intermediate prognosis (according to IMDC) and eligible for watchful waiting were included. Patients underwent 3 scans, i.e. ceCT, 89Zr-girentuximab and 18F-FDG PET. So far, baseline scans of 29 of the 40 pts to be accrued were independently reviewed by 3 experienced readers. Lesions by ceCT were defined positive according to RECIST1.1. For lesions with prominent uptake of 89Zr-girentuximab or 18F-FDG, maximum Standardized Uptake Values (SUVmax) were calculated. Analyses were performed on a lesion level, taking clustering of data within patients and lesions into account.
Results
In total 325 lesions were detected by at least one modality (mean 11(2-33) per pt); ceCT detected 52% (95%CI:45;58), 18F-FDG PET 61% (95%CI:55;67) and 89Zr-girentuximab PET 69% (95%CI:63;74). Differences in lesion detection varied across organ sites(p < 0.001). Lesions were visualized by ceCT and 18F-FDG PET in all pts,whereas 89Zr-girentuximab PET detected lesions in 27 of 29 pts. Compared to ceCT, 89Zr-girentuximab PET visualized additional lesions in all organ sites. Location was strongly related with 89Zr-girentuximab uptake; highest uptake in kidney and adrenal gland tumor (mean SUVmax 63.2 and 70.3, resp) and lowest uptake in lung and lymph nodes (mean SUVmax 10.9 and 15.0, resp). After correction for location, no relation was observed between 89Zr-girentuximab SUVmax and tumor size, as measured by ceCT, and 18F-FDG SUVmax.
Conclusions
89Zr-girentuximab and 18F-FDG PET visualize additional lesions compared to ceCT, however correlation was poor. The addition of 89Zr-girentuximab or 18F-FDG PET might aid in deciding to either delay or start systemic treatment.
Clinical trial identification
NCT02228954.
Legal entity responsible for the study
Radboud University Medical Center (Radboudumc).
Funding
Supported by the Dutch Cancer Society.
Editorial Acknowledgement
Supported by the Dutch Cancer Society
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract